STOCK TITAN

Paragon 28 Inc - FNA STOCK NEWS

Welcome to our dedicated page for Paragon 28 news (Ticker: FNA), a resource for investors and traders seeking the latest updates and insights on Paragon 28 stock.

Overview of Paragon 28 Inc

Paragon 28 Inc (FNA) is a specialized medical device company dedicated exclusively to the foot and ankle orthopedic segment. Established in 2010 with a clear mission to blend surgical innovation and quality, the company has built a comprehensive portfolio of surgical solutions targeting complex foot and ankle procedures. Utilizing advanced technologies in orthopedic implants and surgical instrumentation, Paragon 28 aims to set a benchmark in innovation and operational efficiency within the medical device industry.

Mission and Core Values

From its humble beginnings as a small, family-based business, Paragon 28 has consistently maintained its core ideals of innovation, quality, and dedicated service. The company's name is a tribute to its exclusive focus on foot and ankle surgery, with the number '28' symbolizing the anatomical complexity of the human foot. Central to its mission is the drive to advance the science of foot and ankle surgery by integrating diverse surgical philosophies from global thought leaders, ensuring that each surgical solution meets stringent biomechanical and clinical standards.

Comprehensive Product Portfolio

Paragon 28 offers an extensive suite of nearly 80 proprietary surgical product systems. These include a range of orthopedic devices such as plates, plating systems, screws, staples, and nails. These products are meticulously designed to address a variety of foot and ankle procedures including:

  • Ankle reconstruction and fixation for complex fractures and musculoskeletal trauma
  • Fracture fixation solutions that ensure stability and promote healing
  • Procedural instrumentation for deformity corrections, hallux valgus, hammertoe, and flatfoot conditions
  • Innovative solutions for specialized conditions such as Charcot foot and progressive collapsing foot deformity

Operational Excellence and Distribution

The company leverages a dedicated and highly trained sales and distribution network to ensure that its advanced orthopedic devices reach a wide network of surgical centers and hospitals, primarily within the United States. This customer-centric approach, combined with efficient operational practices, allows Paragon 28 to address the dual challenges of increasing pricing pressures and reimbursement complexities within the healthcare sector.

Competitive Position and Industry Impact

Operating within the dynamic and competitive landscape of orthopedics, Paragon 28 has distinguished itself through its unwavering focus on the foot and ankle segment. By prioritizing innovation and tailoring its product offerings to meet the precise needs of both patients and surgeons, the company has established a strong operational niche. Its strategy of blending global surgical insights with a rigorous quality framework enables it to create products that are not only clinically relevant but also easily reproducible in diverse surgical settings. This distinctive positioning highlights the company’s commitment to improving patient outcomes while maintaining operational efficiency.

Strategy and Business Model

Paragon 28's business model is anchored in its commitment to three primary pillars:

  • Creation and Innovation: Investing in research and development to refine surgical techniques and develop devices that address specific clinical challenges in the foot and ankle spectrum.
  • Focused Service: Establishing a robust distribution network that ensures timely delivery and superior customer service, which is critical for high-stakes surgical environments.
  • Efficient Practices: Implementing operational efficiencies to navigate challenges related to evolving reimbursement frameworks and pricing pressures, thereby sustaining a cycle of quality and innovation.

Expertise and Authoritativeness

The company's process of integrating varied surgical philosophies into its product design reflects deep industry expertise. Paragon 28’s commitment to ongoing research and development, along with its emphasis on user-friendly yet technologically advanced products, positions it as a trusted name among orthopedic surgeons. The company’s continuous efforts in refining its product systems set a high standard of care in the specialized field of foot and ankle surgery.

Understanding the Technology and Innovation

In the realm of medical devices, technological innovation is crucial. Paragon 28 harnesses cutting-edge manufacturing techniques and research-driven insights to build devices that enhance surgical precision and reliability. This detailed approach ensures that each product not only conforms to current clinical requirements but also anticipates the nuanced challenges surgeons face during delicate procedures. The application of advanced orthopedic implant technologies and state-of-the-art design principles underscores the company’s commitment to facilitating optimal patient outcomes.

Market Significance and Industry Relevance

Although Paragon 28 operates within a specialized niche of the orthopedic implant market, the company’s influence is profound due to its unwavering focus on quality, innovation, and customer service. Its strategic approach, combined with a suite of versatile surgical solutions, effectively addresses critical gaps in the foot and ankle surgical procedural space. This specialization allows the company to serve a targeted customer base that includes orthopedic surgeons, hospitals, and outpatient surgical centers, all of which rely on dependable and innovative surgical solutions to improve patient care.

Conclusion

In summary, Paragon 28 Inc stands as a comprehensive, innovation-driven entity in the orthopedic medical device arena. Its focused mission, extensive product portfolio, and commitment to blending global surgical insights with efficient, reliable service have positioned it as a pivotal player in addressing the challenges of foot and ankle surgery. Through its attention to detail in both product development and operational execution, Paragon 28 offers a detailed case study of how concentrated expertise can drive significant advancements in medical technology.

Rhea-AI Summary
Paragon 28, Inc. (NYSE: FNA) announced preliminary unaudited net revenue for the fourth quarter and full year ended December 31, 2023. The fourth quarter is expected to be in the range of $60.3 to $60.6 million, with a reported growth of approximately 17% to 18% compared to the same period in 2022. The full year net revenue is expected to be in the range of $216.1 to $216.4 million, representing reported and constant currency growth of approximately 19% and 20%, respectively, compared to 2022. The financial results are preliminary and subject to finalization.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.62%
Tags
none
-
Rhea-AI Summary
Paragon 28, Inc. (NYSE: FNA) has announced the launch of the Grappler® Knotless Anchor System and Bridgeline™ Tape, aimed at enhancing the company's position in the fast-growing foot and ankle specific soft tissue market in 2024 and beyond.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.85%
Tags
none
-
Rhea-AI Summary
Paragon 28, Inc. (FNA) to present at 42nd Annual J.P. Morgan Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.35%
Tags
conferences
Rhea-AI Summary
Paragon 28, Inc. (NYSE: FNA) Launches BEAST™ Cortical Fibers, a biologic product designed to aid cellular attachment, differentiation, and bone formation. The press release highlights the product's porous structure, flexibility, and ability to support efficient bone remodeling. The company's biologics product offering is further strengthened with this addition, providing innovative solutions for reconstruction and trauma in foot and ankle surgical applications.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.31%
Tags
none
-
Rhea-AI Summary
Paragon 28, Inc. (NYSE: FNA) announces the launch of its JAWS™ Great White Staple System, offering increased strength and stability for osteotomy or fusion sites. The staples feature an ultra-low-profile bridge with enhanced surface area to minimize soft tissue irritation, providing 400 times the fatigue life of a competitive nitinol staple. The shoulders of the staple work in conjunction with the inserter, allowing full seating prior to compression activation, limiting the need to tamp. Paragon 28’s CEO, Albert DaCosta, expressed excitement about expanding their staple offering to address midfoot and hindfoot reconstruction complexities, enhancing market position in these segments. The addition of the JAWS™ Great White Staple System complements Paragon 28’s hindfoot solutions product offering, providing innovative ankle solutions for trauma, arthritis, and limb salvage.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.91%
Tags
none
-
Rhea-AI Summary
Paragon 28, Inc. (NYSE: FNA) announces the addition of a second trailer to its nationwide mobile lab training program, providing a state-of-the-art, 5 station, cadaveric training facility to accommodate up to 25 surgeons. The mobile lab will host over 70 training sessions in approximately 65 US cities during quarter four of 2023, following a successful kick-off in July 2022. CEO Albert DaCosta emphasizes the program's effectiveness in supporting the company's growing product portfolio and surgeon customers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.91%
Tags
none
Rhea-AI Summary
Paragon 28, Inc. (NYSE: FNA) secures $150 million credit facility from Ares Capital Corporation, replacing existing $90 million senior credit facility. The non-dilutive facility includes $100 million in term loans and a $50 million revolving credit facility, reinforcing the company's pathway to cash flow break-even.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.15%
Tags
none
-
Rhea-AI Summary
Paragon 28, Inc. (NYSE: FNA) reported Q3 2023 financial results with $52.8 million net revenue, 14.7% growth, and reaffirmed 2023 net revenue guidance of $214-218 million, representing 19-20% growth.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.15%
Tags
-
Rhea-AI Summary
Paragon 28, Inc. (NYSE: FNA) announced that its Chairman and CEO, Albert DaCosta, and CFO, Steve Deitsch, will be presenting at two upcoming investor conferences. They will participate in the Stephens Annual Investment Conference on November 15, 2023, and the 35th Annual Piper Sandler Healthcare Conference on November 28, 2023. The fireside chats will be available for live and archived webcasts on the company's website at ir.paragon28.com.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.86%
Tags
conferences
Rhea-AI Summary
Paragon 28, Inc. to report financial results for Q3 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.2%
Tags
conferences earnings

FAQ

What is the current stock price of Paragon 28 (FNA)?

The current stock price of Paragon 28 (FNA) is $13.06 as of March 12, 2025.

What is the market cap of Paragon 28 (FNA)?

The market cap of Paragon 28 (FNA) is approximately 1.1B.

What does Paragon 28 Inc specialize in?

Paragon 28 Inc is dedicated exclusively to the foot and ankle orthopedic segment, focusing on developing, distributing, and selling innovative surgical devices.

What types of products does Paragon 28 offer?

The company offers a wide range of orthopedic implants including plates, plating systems, screws, staples, and nails designed for various foot and ankle procedures.

How does Paragon 28 generate revenue?

Revenue is generated through the sale of its specialized medical devices to hospitals, surgical centers, and orthopedic professionals, supported by a dedicated distribution network.

What are the core values of Paragon 28 Inc?

The company emphasizes innovation, quality, and customer service, with deep-rooted family values and a mission to advance foot and ankle surgery procedures.

How does Paragon 28 maintain industry expertise?

By integrating diverse surgical philosophies and continuously investing in research and development, Paragon 28 ensures its products meet high biomechanical and clinical standards.

What distinguishes Paragon 28 in the competitive orthopedic market?

Its exclusive focus on the foot and ankle segment, comprehensive suite of nearly 80 product systems, and a strong emphasis on quality and innovation set it apart from broader orthopedic device companies.

Who are the primary customers of Paragon 28?

The primary customers include orthopedic surgeons, hospitals, and outpatient surgical centers that rely on advanced, specialized solutions for foot and ankle procedures.

How does Paragon 28 address the challenges in the healthcare market?

The company employs efficient operational practices and maintains a dedicated distribution network to manage pricing pressures and meet evolving reimbursement demands, ensuring continued innovation and service excellence.
Paragon 28 Inc

NYSE:FNA

FNA Rankings

FNA Stock Data

1.10B
57.22M
40.58%
60.94%
4.45%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States
ENGLEWOOD